Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 393,710 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Sunshine Biopharma Inc | SBFM | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.21 | 22.58% | 1.14 | 04:09:11 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.93 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 1,455 | 393,710 | - | 0.92 - 140.00 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 04:09:11 | formt | 100 | $ 1.14 | USD |
Sunshine Biopharma Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 23.62M | 25.68M | - | 24.09M | -4.51M | -0.18 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Sunshine Biopharma News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SBFM Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.55 | 3.68 | 0.92 | 1.50 | 7,536,780 | -2.41 | -67.89% |
| 1 Month | 5.71 | 13.25 | 0.92 | 9.07 | 30,128,059 | -4.57 | -80.04% |
| 3 Months | 25.50 | 26.99 | 0.92 | 8.23 | 26,271,934 | -24.36 | -95.53% |
| 6 Months | 32.30 | 32.90 | 0.92 | 8.35 | 12,274,618 | -31.16 | -96.47% |
| 1 Year | 67.90 | 140.00 | 0.92 | 12.63 | 6,474,721 | -66.76 | -98.32% |
| 3 Years | 275.00 | 987.00 | 0.92 | 174.43 | 4,508,197 | -273.86 | -99.59% |
| 5 Years | 275.00 | 987.00 | 0.92 | 174.43 | 4,508,197 | -273.86 | -99.59% |
Sunshine Biopharma Description
| Sunshine Biopharma Inc is a pharmaceutical company focused on the research, development, and commercialization of oncology and antiviral drugs. In addition, it is engaged in the development and commercialization of science-based nutritional supplements. The company is focusing on the development of the licensed Adva-27a anticancer drug, a small molecule that has been shown to be exceptionally effective at destroying Multidrug-Resistant Cancer Cells, including Pancreatic Cancer cells (Panc-1), Small-Cell Lung Cancer cells (H69AR), Breast Cancer cells (MCF-7/MDR) and Uterine Sarcoma cells (MES-SA/Dx5). |
